All In Biotech

Drug Trial Radar · NCT03393884

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal IMNN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Last checked: Nov 19, 2026Latest source record: May 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Sep 5, 2018

Primary completion

Jul 25, 2024

Study completion May 30, 2026

Sponsor

Lead sponsor
ImunonIndustry
Sponsor type
Industry
First posted
Jan 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open label, multicenter trial to evaluate the safety, dosing, efficacy and biological activity of intraperitoneal IMNN-001 plus NACT compared to NACT alone.

Conditions

  • Epithelial Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer

Interventions

  • IMNN-001Biological

    IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer

  • CarboplatinDrug

    AUC 6 IV over 1 hour on Day 1 of each cycle

  • PaclitaxelDrug

    175 mg/m2 IV over 3 hours on Day 1 of each cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PFSTime frame: The primary analysis for PFS will be conducted after at least 80 events have been observed or after all patients have been followed for at least 16 months, whichever is later.

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama Birmingham

    Birmingham, Alabama

  • Mitchell Cancer Institute (University of South Alabama)

    Mobile, Alabama

  • Gynecologic Oncology Associates (Hoag Hospital)

    Newport Beach, California

  • Innovative Clinical Research

    Whittier, California

  • Advent Health

    Orlando, Florida

  • Women's Care Florida

    St. Petersburg, Florida

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Washington University School of Medicine in St. Louis

    St Louis, Missouri

  • MD Anderson at Cooper

    Camden, New Jersey

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Monter Cancer Center

    Lake Success, New York

  • NYU Langone, Long Island

    Mineola, New York

  • NYU Langone

    New York, New York

  • Stephenson Cancer Center - Oklahoma University

    Oklahoma City, Oklahoma

  • Providence Cancer Institute

    Portland, Oregon

  • Sanford Health

    Sioux Falls, South Dakota

  • Chattanooga Women's Health

    Chattanooga, Tennessee

  • The West Clinic

    Germantown, Tennessee

  • Providence Health Care

    Spokane, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • CHUM

    Montreal, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.